ClinicalTrials.gg
CompletedNCT01573013Updated May 12, 2014

Iron Fortification Trail Using NaFeEDTA in Iron Deficient Lead-exposed Children

An interventional study of iron fortified biscuits and iron fortified biscuits in Iron Deficiency and Lead Poisoning, sponsored by Swiss Federal Institute of Technology. Completed at 1 site in Switzerland. Open to participants aged 3 Years to 13 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-05-12.

Sponsored by Swiss Federal Institute of Technology · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
457
Allocation
Randomized
Ages
3 Years to 13 Years
Sex
All
01

Study summary

In a cross-sectional study allotted by the ethical committee of the ETH Zurich, we are investigating the extent of anemia, iron deficiency and lead intoxication in young children. For this purpose an assessment of body lead burden and iron status was conducted in a cohort of individuals residing in areas of presumed high lead exposure. Associations between lead burden and iron status will be investigated in the near future (current status of the study).

In a follow-on intervention study, the effect of iron fortification with and without NaEDTA on blood lead levels in lead-exposed children will be evaluated; and the relative impact of these two strategies on child growth, motor and cognitive test performance will be compared.

This study will investigate the potential use of iron fortification to not only combat anemia but also reduce body lead burden in lead-exposed populations; it specifically investigates whether iron fortification with NaFeEDTA could have additional beneficial effects to iron alone.

Read the detailed description

Introduction Coexisting chronic lead poisoning and iron deficiency anemia (IDA) are common in urban areas in developing regions, particularly in young children. In urban Morocco, anemia affects more than 1/3rd of schoolchildren and lead exposure is high. Lead poisoning and IDA both impair cognitive development and educability and may therefore have substantial health, social and economic costs on developing countries.

Iron status alters susceptibility to gastrointestinal lead exposure; absorption of lead is sharply increased in children with IDA. IDA upregulates the divalent metal transporter trans-port protein (DMT-1) and increases lead absorption. Thus, iron fortification to reduce IDA may also reduce lead absorption and be an effective strategy to accompany environmental lead abatement. The optimal iron compound for wheat flour is currently debated, and although elemental iron compounds are commonly used, they may be only poorly absorbed in the face of inhibitory compounds found in wheat flour.

A form of chelated iron, NaFeEDTA, is a promising iron fortificant that is recommended for wheat flour fortification. It is also a lead chelator. It may be superior to other iron fortificants in its ability to reduce body lead burden, due to:

  1. its iron is highly bioavailable in the face of dietary inhibitors (such as phytic acid in wheat flour); and
  2. potentially, its ability to chelate lead in the gut and bloodstream. Thus, it may be a good choice for fortification of wheat flour in Morocco, particularly in urban areas, to both reduce IDA and lower body lead.

Study aims and objectives:

  1. Assessment of body lead burden and iron status in a cohort of individuals residing in areas of presumed high lead exposure. Investigation of associations between lead burden and iron status.
  2. Comparison of effect of iron fortification with and without NaEDTA on body lead and iron status in lead-exposed children; and the relative impact on cognition.

Study hypotheses:

The prevalence of iron deficiency and elevated blood lead will be high in children in this region.

  1. Body lead burden, as assessed by blood lead levels and urinary lead and delta-aminolevulinic acid (ALA), will be higher in individuals with poorer iron status.
  1. Poor iron status will be associated with low intakes of bioavailable iron. 4) Greater severity of iron deficiency and/or higher body lead in children will predict poorer performance on cognitive and motor tests, and these conditions will interact to predict poorer performance.

Study design:

Our studies will be carried out in one of the four sub-economic areas, that were previously used in the baseline assessment in and near Marrakesh, Morocco (exact site still needs to be determined according to extend of lead contamination on the level of human population). Body lead burden and iron status will be determined, and associations between these examined using a cross-sectional design. For this purpose, blood and urine samples will be collected from two groups (preschool and school-aged children), residing in an area of high lead exposure.

Study design:

An 8-month intervention study in iron deficient, lead-exposed school children (n=500) will be designed to investigate whether iron fortification to reduce IDA may also reduce lead absorption and be an effective strategy to accompany environmental lead abatement.

For this purpose these children will be divided into four groups to receive a daily fortified baked snack containing either: 1) 66.4 mg NaFeEDTA ; 2) 52.2 mg Na2EDTA dehydrate; 3) 27.1 mg FeSO4 ; or 4) no fortificants.

02

Conditions studied

  • Iron Deficiency
  • Lead Poisoning

Keywords

  • iron deficiency
  • Lead poisoning
  • cognitive development
  • motor activity
03

In context

Iron Deficiencies

386 studies on the registry are indexed under Iron Deficiencies; 80 are open to participants now.

This study's enrollment of 457 is above the median of 99 across 301 interventional studies indexed under Iron Deficiencies.

Browse Iron Deficiencies studies →

Lead sponsor

Swiss Federal Institute of Technology is the lead sponsor of 154 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 13 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • school and preschool children living in a lead-exposed environment with a high prevalence of iron deficiency

Exclusion criteria

Exclusion Criteria:

  • chronic or severe illnesses
  • history of bleeding disorder
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
457 participants (actual)

Study arms

  • Active comparator
    NaFeEDTA treatment, biscuit

    Group receives 10 mg of Fe in form of NaFeEDTA per day. wheat flour based biscuit

    Dietary Supplement: iron fortified biscuits

  • Active comparator
    EDTA treatment, biscuit

    Group receives Na2EDTA enriched biscuit

    Dietary Supplement: iron fortified biscuits

  • Active comparator
    FeSO4 treatment, biscuit

    Group receives 10 mg of iron as FeSo4 per day for 8 months

    Dietary Supplement: iron fortified biscuits

  • Placebo comparator
    control treatment, biscuit

    group receives a biscuit without additional iron

    Dietary Supplement: iron fortified biscuits

Interventions

  • Dietary supplementiron fortified biscuits

    10 mg of iron per day for 8 months, either in the form of NaFeEDTA

  • Dietary supplementiron fortified biscuits

    10 mg of iron per day for 8 months, in the form of FeSo4

  • Dietary supplementiron fortified biscuits

    EDTA fortified biscuit on a daily basis for 8 months

  • Dietary supplementiron fortified biscuits

    control biscuit on a daily basis for 8 months

06

What researchers measure

Primary outcomes

  1. body lead burden

    changes in blood lead levels over time of the intervention

    Time frame: 8 months

Secondary outcomes

  1. Iron status

    changes in iron status (SF,Hb, TfR) before and after intervention

    Time frame: 8 months

  2. cognitive development

    changes in cognitive development (using the K ABC II) before and after intervention

    Time frame: 8 months

07

Study locations

1 site
  • Swiss Federal Institute of Technology (ETH)
    Zurich, 8092, Switzerland
08

References and documents

Publications

  • Bouhouch RR, El-Fadeli S, Andersson M, Aboussad A, Chabaa L, Zeder C, Kippler M, Baumgartner J, Sedki A, Zimmermann MB. Effects of wheat-flour biscuits fortified with iron and EDTA, alone and in combination, on blood lead concentration, iron status, and cognition in children: a double-blind randomized controlled trial. Am J Clin Nutr. 2016 Nov;104(5):1318-1326. doi: 10.3945/ajcn.115.129346. Epub 2016 Oct 12. PubMed 27733396 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2011
First posted
Apr 6, 2012
Start
Sep 2011
Primary completionActual
Jun 2012
CompletionActual
Jun 2012
Last update
May 12, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01573013
Responsible party
Prof. Michael B. Zimmermann (Prof. Dr. med, Swiss Federal Institute of Technology) — Principal investigator
First posted
Apr 6, 2012
Start date
Sep 2011
Primary completion
Jun 2012
Completion
Jun 2012
Last update
May 12, 2014

Study contacts

Michael B Zimmermann, Prof. Dr. med
principal investigator · Swiss Federal Institute of Technology (ETH)

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion